ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,874Medicare Part D Prescriptions Filled, Including Refills

Rank: 88 out of 617

$634K Total Retail Price of All Prescriptions

Rank: 38 out of 617

365 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
44% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 365 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

17% of this provider’s 365 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

2% of this provider’s 7,933 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
FUROSEMIDE 448 392 1 4
SIMVASTATIN 382 345 2 2
WARFARIN SODIUM 340 319 3 7
OMEPRAZOLE 324 244 4 3
LEVOTHYROXINE SODIUM 284 235 5 1
LISINOPRIL 280 211 6 5
AMLODIPINE BESYLATE 272 226 7 6
HYDROCODONE-ACETAMINOPHEN 248 89 S3 8 8
MELOXICAM 234 198 9 24
TRAMADOL HCL 231 151 10 15
TAMSULOSIN HCL 203 158 11 26
METFORMIN HCL 177 143 12 9
CITALOPRAM HBR 174 116 13 18
POTASSIUM CHLORIDE 172 153 14 10
SERTRALINE HCL 168 150 15 20
DONEPEZIL HCL 164 136 16 30
METOPROLOL TARTRATE 154 124 17 11
ATORVASTATIN CALCIUM 147 130 18 14
HYDROCHLOROTHIAZIDE 143 126 19 13
CYMBALTA 138 48 20 49
GABAPENTIN 134 76 21 16
LISINOPRIL-HYDROCHLOROTHIAZIDE 127 100 22 29
ZOLPIDEM TARTRATE 126 62 23 23
MIRTAZAPINE 115 74 24 50
NAMENDA 112 100 25 35
OXYCONTIN 107 18 S2 26 133
PREDNISONE 105 100 27 31
ALLOPURINOL 105 100 27 27
CYCLOBENZAPRINE HCL 97 21 R 29 74
AMITRIPTYLINE HCL 94 53 R 30 56
LANTUS 87 70 31 39
DIOVAN 87 71 31 41
RISPERIDONE 81 44 33 71
METOPROLOL SUCCINATE 76 62 34 12
ALENDRONATE SODIUM 75 62 35 25
BYSTOLIC 70 49 36 64
OXYCODONE-ACETAMINOPHEN 67 29 S2 37 93
BUPROPION HCL SR 62 0 38 202
FLUTICASONE PROPIONATE 61 30 39 36
ADVAIR DISKUS 61 28 39 38
NEXIUM 59 45 41 43
EXELON 58 58 42 156
PAROXETINE HCL 58 31 42 62
FENTANYL 56 25 S2 44 45
CRESTOR 54 29 45 28
RAMIPRIL 52 52 46 67
CARVEDILOL 51 44 47 19
ABILIFY 51 0 47 131
CELEBREX 50 46 49 63
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 27, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.